aTyr Pharma (ATYR) Projected to Post Quarterly Earnings on Tuesday

Key Points

• aTyr Pharma is set to announce its Q2 2025 earnings on August 12th, with analysts predicting a loss of ($0.18) per share.
• Shares of aTyr Pharma have recently traded at $5.03, with a market cap of approximately $447.23 million and significant institutional ownership at 61.72%.
• Recent analyst reports indicate a bullish outlook, with Wells Fargo raising their price target on aTyr Pharma stock to $25.00 and a general average target of $20.20.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) will likely be announcing its Q2 2025 earnings results before the market opens on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last released its earnings results on Tuesday, August 12th. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.04). On average, analysts expect aTyr Pharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

aTyr Pharma Price Performance

Shares of NASDAQ:ATYR traded up $0.06 during trading on Friday, hitting $5.30. 3,227,559 shares of the company were exchanged, compared to its average volume of 5,952,621. The business's 50 day moving average is $5.34 and its 200-day moving average is $4.12. The company has a market capitalization of $471.70 million, a P/E ratio of -6.62 and a beta of 0.94. The company has a quick ratio of 7.79, a current ratio of 7.79 and a debt-to-equity ratio of 0.01. aTyr Pharma has a 1-year low of $1.67 and a 1-year high of $7.29.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on ATYR shares. Wall Street Zen downgraded shares of aTyr Pharma from a "hold" rating to a "sell" rating in a report on Saturday. Wells Fargo & Company increased their price objective on aTyr Pharma from $17.00 to $25.00 and gave the company an "overweight" rating in a report on Friday, June 20th. Finally, HC Wainwright restated a "buy" rating and issued a $35.00 price objective on shares of aTyr Pharma in a report on Wednesday, June 4th. One equities research analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, aTyr Pharma presently has an average rating of "Moderate Buy" and a consensus price target of $20.20.

Institutional Investors Weigh In On aTyr Pharma

A number of hedge funds have recently modified their holdings of ATYR. Creative Planning purchased a new position in aTyr Pharma in the 2nd quarter valued at approximately $74,000. Goldman Sachs Group Inc. grew its position in aTyr Pharma by 46.0% in the first quarter. Goldman Sachs Group Inc. now owns 382,317 shares of the company's stock worth $1,155,000 after acquiring an additional 120,496 shares in the last quarter. Finally, Millennium Management LLC grew its position in aTyr Pharma by 334.5% in the first quarter. Millennium Management LLC now owns 1,599,041 shares of the company's stock worth $4,829,000 after acquiring an additional 1,231,052 shares in the last quarter. Institutional investors own 61.72% of the company's stock.

About aTyr Pharma

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.